<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>The use of inhaler devices in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">The use of inhaler devices in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">The use of inhaler devices in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dean Hess, RRT, PhD, FAARC, FCCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajiv Dhand, MD, FCCP, FACP, FAARC, FRSM, ATSF</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne E Dixon, BM, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inhaler devices are the major method for delivery of medications for asthma and chronic obstructive pulmonary disease (COPD), but their effectiveness can be compromised if the patient uses the inhaler device incorrectly [<a href="#rid1">1,2</a>]. </p><p>The magnitude of incorrect inhaler use has been well documented; in several studies, less than one-half of the patients used their inhaler correctly [<a href="#rid3">3-13</a>], with little to no improvement in rates of correct inhaler technique over the past 40 years [<a href="#rid13">13</a>]. Moreover, several investigators have reported low levels of adherence to inhaled therapy [<a href="#rid14">14,15</a>]. Errors in inhaler technique and poor adherence lead to poor control of asthma and COPD, with increased risk of hospitalization, emergency department visits, and oral glucocorticoid use [<a href="#rid1">1,2,12,16</a>]. In contrast, higher patient satisfaction with their inhaler device is associated with better adherence to therapy and improved clinical outcomes [<a href="#rid17">17</a>].</p><p>The use of inhaler devices by adults will be presented here. More general discussions of the delivery of inhaled medication via nebulizers and what patients need to know about their asthma are presented separately  (<a class="graphic graphic_table graphicRef71527" href="/d/graphic/71527.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/552.html" rel="external">"Delivery of inhaled medication in adults"</a> and  <a class="medical medical_review" href="/d/html/566.html" rel="external">"Asthma education and self-management"</a>.)</p><p class="headingAnchor" id="H74579844"><span class="h1">TYPES OF INHALER DEVICES</span><span class="headingEndMark"> — </span>Inhaler devices are used to deliver a variety of inhaled medications, including beta-agonists, anticholinergics, glucocorticoids, antibiotics, prostaglandin analogs, nicotine, insulin, <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a>, antipsychotics, and levodopa. Three main types of inhaler devices are available: the pressurized metered dose inhaler (pMDI), the dry powder inhaler (DPI), and the soft mist inhaler (SMI) [<a href="#rid18">18-20</a>].</p><p class="headingAnchor" id="H85082029"><span class="h2">Pressurized metered dose inhalers</span><span class="headingEndMark"> — </span>pMDI devices usually consist of a pressurized canister, a metering valve and stem, and a mouthpiece actuator  (<a class="graphic graphic_picture graphicRef62613" href="/d/graphic/62613.html" rel="external">picture 1</a>). The pressurized canister contains the drug suspended in a mixture of propellants, surfactants, preservatives, flavoring agents, and dispersal agents. Following adoption of the Montreal Protocol, an international agreement to ban chlorofluorocarbons (CFCs), the CFC-free propellant hydrofluoroalkane (HFA)-134a has replaced CFC-containing devices [<a href="#rid20">20-34</a>]. pMDIs can be formulated as solutions, suspensions, or co-suspensions, with solutions typically having a finer aerosol particle size compared with suspensions [<a href="#rid34">34,35</a>]. Delivery of most aerosol medications to the lungs is comparable between HFA and CFC devices used in the past, although a few of the HFAs deliver a greater portion of the dose than the previous CFC pMDI [<a href="#rid30">30,36-41</a>]. </p><p>The co-suspension technology platform overcomes some of the formulation challenges of combining respiratory drugs in suspension pMDIs [<a href="#rid42">42</a>]. This technology employs spray-dried porous phospholipid particles on which drug crystals are reversibly associated to achieve a more uniform suspension in propellant. pMDIs formulated with co-suspension technology provide more consistent drug delivery with single drugs, as well as dual and triple drug combinations [<a href="#rid43">43,44</a>]. Furthermore, these pMDIs are less influenced by patient-handling errors, such as the need for shaking prior to use.</p><p>A Redihaler is a breath-actuated pMDI that is activated quite differently from other pMDIs. The dose is ready for inhalation when the cap is opened. When the patient breathes in thorough the mouthpiece, a dose is delivered. The cap must be closed for the next dose. This device should not be shaken and there is no need for priming. The most widely available agent that is paired with a Redihaler is <a class="drug drug_general" data-topicid="9068" href="/d/drug information/9068.html" rel="external">beclomethasone</a> (brand name QVAR). The Redihaler cannot be used with a spacer or valved holding chamber.</p><p class="headingAnchor" id="H85082036"><span class="h2">Dry powder inhalers</span><span class="headingEndMark"> — </span>DPIs are breath-actuated devices that deliver micronized drug particles with a mass median aerodynamic diameter (MMAD) of less than 5 micrometers, which usually are aggregated with larger carrier particles (such as lactose or glucose)  (<a class="graphic graphic_picture graphicRef57922" href="/d/graphic/57922.html" rel="external">picture 2</a>) [<a href="#rid45">45-47</a>]. Drug is delivered to the airways by the inhalation of air over a punctured capsule, blister, or reservoir [<a href="#rid45">45-47</a>]. DPIs have various designs and resistances, but generally, inspiratory flows of 30 to 60 L/minute are required to disaggregate and aerosolize the drug [<a href="#rid48">48-50</a>].</p><p>The controlling factor in a patient’s ability to effectively operate a DPI is the maximum inspiratory pressure they can achieve [<a href="#rid51">51</a>]. Inspiratory pressure generation is primarily dependent on the strength of the respiratory muscles [<a href="#rid51">51,52</a>]. While achieving an adequate maximum inspiratory pressure drop (or flow) is reassuring, optimal dosing from DPIs requires training of patients on the correct technique for each DPI [<a href="#rid19">19</a>].</p><p>Additional aspects that influence the effectiveness of DPIs include the formulation, oropharyngeal deposition, drug dissolution, and clearance mechanisms [<a href="#rid47">47,53</a>]. Notably, some powder formulations are extremely sensitive to moisture, and exposure to high ambient humidity could decrease generation of fine particles even with an adequate inspiratory airflow [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H347194473"><span class="h2">Soft mist inhalers</span><span class="headingEndMark"> — </span>Soft mist inhalers (SMI) are propellant-free mechanical devices that are slightly larger than a conventional pMDI  (<a class="graphic graphic_picture graphicRef91634" href="/d/graphic/91634.html" rel="external">picture 3</a>) [<a href="#rid55">55</a>]. Rotating the lower half of the device compresses a spring and draws a measured amount of drug solution into the dosing system. After priming, the spring is released by pressing a button, creating pressure within the device that forces the liquid through a nozzle that has two narrow outlet channels (8 micrometers in diameter) etched using microchip technology [<a href="#rid56">56</a>]. The two fine jets of liquid produced by the channels converge at an optimized angle and their impact generates a fine mist that moves slowly (about 0.8 m/s) and lasts about 1.2 seconds [<a href="#rid57">57</a>]. Thus, the aerosol produced by an SMI has a low velocity and six times more sustained duration than a pMDI [<a href="#rid58">58</a>]. Dose delivery and particle fraction with an SMI are independent of inspiratory flow, and shaking is not necessary prior to using the device.</p><p>The lower velocity of the aerosol produced by an SMI decreases oropharyngeal deposition and enhances lung deposition [<a href="#rid59">59</a>]. The longer duration of the aerosol cloud increases the window for successful inhalation, thus reducing problems with coordination between actuation and inhalation [<a href="#rid60">60</a>]. These properties permit the nominal dose to be reduced. Combivent (20 micrograms <a class="drug drug_general" data-topicid="8570" href="/d/drug information/8570.html" rel="external">ipratropium</a> bromide and 100 micrograms <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a>) in an SMI was approved with the recommended dose of 1 inhalation four times per day being essentially one-half that delivered with a Combivent pMDI (2 puffs four times per day). Similarly, the increased lung deposition allows a reduction of the recommended daily dose of <a class="drug drug_general" data-topicid="10300" href="/d/drug information/10300.html" rel="external">tiotropium</a> bromide from 18 micrograms delivered from the HandiHaler DPI to 5 micrograms (2 puffs of 2.5 micrograms each) delivered by the SMI [<a href="#rid61">61,62</a>]. SMIs can be employed with a valved holding chamber (VHC) and a face mask in children [<a href="#rid63">63</a>]. Several formulations are available including ones containing short-acting bronchodilators, long-acting bronchodilators, and combinations. </p><p class="headingAnchor" id="H62570469"><span class="h1">SPACERS AND HOLDING CHAMBERS</span><span class="headingEndMark"> — </span>Using a spacer or valved holding chamber (VHC) with a pressurized metered dose inhaler (pMDI) allows the velocity of particles to decrease before reaching the mouth, which decreases the amount of oropharyngeal deposition  (<a class="graphic graphic_picture graphicRef58957" href="/d/graphic/58957.html" rel="external">picture 4</a>) [<a href="#rid20">20,64,65</a>]. Use of a VHC also allows sequential actuation and inhalation as the aerosol is retained in the chamber after actuation of the pMDI. We typically prescribe a VHC for patients with difficulty coordinating actuation and inhalation and for those using pMDIs containing glucocorticoids, especially if the dose is in the medium to high range. Spacers are less expensive than VHCs and may be a better option in resource-limited settings, although they do not allow for sequential actuation and inhalation. Spacers and VHCs require a prescription from a clinician.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spacers</strong> – A spacer is usually an open-ended tube or bag that is of sufficient volume to allow the aerosol plume from the pMDI to expand and the propellant to evaporate. The spacer should be at least 100 to 700 mL in volume and should provide a distance of 10 to 13 cm between the pMDI nozzle and the mouth [<a href="#rid66">66,67</a>]. By dispersing the aerosol into the spacer, the individual medication droplets experience slight evaporative loss of the propellant, which decreases the droplet size and thereby decreases oral deposition of the aerosol. The spacer holds the medicine aerosol long enough for patients to inhale slowly and deeply  (<a class="graphic graphic_picture graphicRef58957" href="/d/graphic/58957.html" rel="external">picture 4</a>) [<a href="#rid68">68</a>]. Spacers can increase the bioavailability of inhaled medication [<a href="#rid69">69</a>]. However, the dose can be lost or diluted if the patient exhales into the spacer prior to inhalation of the dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valved holding chambers</strong> – The VHC is a specialized spacer that incorporates a one-way valve between the chamber and the mouthpiece. This design permits sequential actuation and inhalation as the aerosol is retained in the chamber after actuation of the pMDI. In addition, the valve prevents the exhaled breath from entering the chamber, so the aerosol medication is held in the chamber to allow a second or third inhalation, if needed. Commonly used VHCs include rigid devices, such as the AeroChamber, and plastic collapsible holding chambers, such as the InspirEase bag  (<a class="graphic graphic_picture graphicRef58957" href="/d/graphic/58957.html" rel="external">picture 4</a>). Upgrades to VHCs include improvements in valve design, visual feedback of inspiratory flow, an auditory alert if the patient inhales too quickly, and addition of an anti-static resin to the polymer from which the device is made [<a href="#rid70">70</a>]. </p><p></p><p class="bulletIndent1">Retention of aerosol within the chamber of a VHC for a finite time post pMDI actuation produces a finer aerosol because of impaction of large particles and partial evaporation of propellant from the aerosol droplets [<a href="#rid71">71</a>]. </p><p></p><p class="bulletIndent1">Several issues are important to the correct use of a VHC. Only one actuation should be placed into the chamber for each inhalation, as multiple actuations into the chamber reduces the overall amount of drug inhaled [<a href="#rid72">72</a>]. The time between actuation and inhalation should be as short as possible because the aerosol is lost to the walls of the device due to gravitational sedimentation, inertial impaction, and electrostatic charge [<a href="#rid72">72,73</a>]. MDIs that generate fine particle aerosols, such as HFA-beclomethasone dipropionate, may be less affected by a delay in inhalation from a VHC [<a href="#rid41">41,73</a>]. </p><p></p><p class="bulletIndent1">Electrostatic charge can be minimized by washing the device in detergent, rinsing, and allowing it to air dry. However, the relative effects of detergent coating can vary depending on the VHC and pMDI formulations [<a href="#rid74">74,75</a>]. Alternatively, multiple doses may be actuated into a new spacer before use to minimize the static charge. VHCs made of nonelectrostatic materials are available, but these are costlier. Observations from retrospective, real-life studies in patients with asthma suggest that use of antistatic VHCs could improve clinical outcomes (such as exacerbation rates, time to first exacerbation, need for emergency department visits) compared with use of MDIs with nonantistatic spacers [<a href="#rid76">76</a>].</p><p></p><p>Despite the variety and popularity of spacer devices, little information is available on their relative performance [<a href="#rid64">64,77</a>]. In general, larger-sized spacers appear more effective than smaller ones, but proper technique remains important for obtaining optimal drug delivery  (<a class="graphic graphic_table graphicRef103302" href="/d/graphic/103302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef103303" href="/d/graphic/103303.html" rel="external">table 3</a>) [<a href="#rid78">78,79</a>]. A point of controversy is whether or not a VHC is necessary for delivery of nonsteroid drugs when the patient demonstrates good technique with the pMDI alone, as the use of the chamber adds cost and complexity [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/d/html/552.html" rel="external">"Delivery of inhaled medication in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">COMMON PROBLEMS WITH INHALER DEVICES</span><span class="headingEndMark"> — </span>The main problems with the use of inhaler devices, such as metered dose and dry powder inhalers, are upper airway deposition and poor coordination between actuation and inhalation. A less common problem is that of an insufficient breath-hold after inhalation of the medication. Poor adherence with use of inhalers compromises the effectiveness of inhaled therapies in patients with asthma and COPD.</p><p class="headingAnchor" id="H3"><span class="h2">Upper airway deposition</span><span class="headingEndMark"> — </span>Metered dose inhalers (MDIs) tend to spray out medication more quickly than the patient can inhale. In addition, some patients do not inhale long enough after actuation of the device. As a result, a substantial amount of the medication is deposited in the back of the throat or on the tongue. Oropharyngeal deposition results in inefficient medication delivery and, with inhaled glucocorticoids, may cause hoarseness and thrush. It has been estimated that, in most patients, only about 10 percent of the dose reaches the lungs, while 80 percent remains in the oropharynx, although this varies depending on the preparation and delivery device [<a href="#rid4">4,39,40,81-83</a>].</p><p>Use of hydrofluoroalkane (HFA) MDIs may diminish oropharyngeal deposition as they tend to deliver a greater proportion of the actuated dose to the airways in the lungs and less to the oropharynx compared with chlorofluorocarbon (CFC) MDIs [<a href="#rid39">39-41,82,84</a>].</p><p>Another way to address this problem is to add a spacer device or valved holding chamber (VHC), which can decrease the oral deposition of medicine [<a href="#rid4">4,67</a>]. In a study comparing HFA and CFC formulations of <a class="drug drug_general" data-topicid="9068" href="/d/drug information/9068.html" rel="external">beclomethasone</a> with and without a VHC or large volume spacer, the VHC and spacer decreased oropharyngeal deposition from approximately 80 to 20 percent [<a href="#rid41">41</a>]. (See <a class="local">'Spacers and holding chambers'</a> above.)</p><p class="headingAnchor" id="H4"><span class="h2">Actuation-inhalation coordination</span><span class="headingEndMark"> — </span>The other major cause of inefficient delivery of inhaled medications is lack of coordination between actuation and inhalation. The use of a VHC allows the patient to sequentially activate the inhaler into the chamber and then inhale the medication. In addition, dry powder inhalers (DPIs) that contain the medication in the form of a powder are breath actuated. The force of the patient's inhalation draws the powder into the lungs  (<a class="graphic graphic_picture graphicRef57922" href="/d/graphic/57922.html" rel="external">picture 2</a>) [<a href="#rid53">53,72</a>]. (See  <a class="medical medical_review" href="/d/html/552.html" rel="external">"Delivery of inhaled medication in adults", section on 'Dry powder inhalers (DPI)'</a>.)</p><p class="headingAnchor" id="H62571105"><span class="h2">Insufficient breath-hold</span><span class="headingEndMark"> — </span>The usual advice is for a 5 to 10 second breath-hold at the end of inhalation from either a pMDI or a DPI. In support of this recommendation, a study examining the effect of breath-hold on drug delivery from HFA pMDIs containing <a class="drug drug_general" data-topicid="9068" href="/d/drug information/9068.html" rel="external">beclomethasone</a> found that lung deposition was reduced by 16 percent with a 1 second versus a 10 second breath-hold [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H3733488103"><span class="h2">Poor adherence to inhaler use</span><span class="headingEndMark"> — </span>Lack of adherence to the prescribed therapy is more prevalent among patients with asthma or COPD compared with patients with other chronic diseases [<a href="#rid85">85</a>]. In patients with asthma or COPD, nonadherence rates to inhaled medications have been reported in as high as 50 to 80 percent [<a href="#rid15">15,16</a>]. A variety of factors, both unintentional and intentional, contribute to poor adherence by patients [<a href="#rid15">15,86</a>]. The Ascertaining Barriers to Compliance taxonomy identifies lack of adherence to either failure to initiate therapy; poor implementation due to infrequent use, incorrect inhaler technique or incorrect dose; or lack of persistence leading to early discontinuation after initiation [<a href="#rid87">87</a>]. This classification helps to identify possible reasons for nonadherence among patients and adopt an individualized approach to address them more effectively.</p><p>Nonadherence to inhaled therapies diminishes symptom control in patients with asthma or COPD leading to an increase in acute exacerbations and hospitalizations, unnecessary escalation of treatment, and greater morbidity and mortality [<a href="#rid85">85</a>]. Assessment of adherence is complex. Measures of adherence that were used in the past, such as patient self-reports or canister weighing, tend to overestimate inhaler use [<a href="#rid88">88,89</a>]. Introduction of electronic monitoring devices ("Smart Inhalers") allows collection of real-time and objective data on inhaler use that reliably detects nonadherence by patients [<a href="#rid90">90</a>], but several issues must be resolved before their use can be implemented in routine clinical practice [<a href="#rid91">91</a>]. Interventions to improve adherence with inhaled therapy have a positive impact on clinical outcomes of patients. Achieving good (&gt;80 percent) adherence with inhaler use is associated with significant reductions in health care utilization (less exacerbations, hospitalizations, and emergency department visits), improvements in lung function and quality of life, and decrease in the economic and societal impact of asthma and COPD [<a href="#rid16">16,92,93</a>].</p><p class="headingAnchor" id="H5"><span class="h1">TEACHING INHALER USE SKILLS</span><span class="headingEndMark"> — </span>The National Asthma Education Program (NAEP) recommends that patients be taught inhaler use in the following manner [<a href="#rid94">94</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The clinician should first demonstrate the steps on the checklist.</p><p class="bulletIndent1"><span class="glyph">●</span>The patient then practices in front of the clinician so that errors may be corrected.</p><p class="bulletIndent1"><span class="glyph">●</span>The patient's technique should be evaluated periodically and corrections made as necessary.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be positively reinforced for correct inhaler technique. Instructions should be reviewed and repeated over time to reinforce the correct inhaler technique [<a href="#rid95">95</a>].</p><p></p><p>At follow-up visits, the best way to assess if a patient uses the inhaler correctly is to observe the patient. There are a number of published checklists or criteria for correct use of the various types of inhalers  (<a class="graphic graphic_table graphicRef103302" href="/d/graphic/103302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef103303" href="/d/graphic/103303.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef51020" href="/d/graphic/51020.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef93600" href="/d/graphic/93600.html" rel="external">table 5</a>) [<a href="#rid3">3,4,94,96</a>]. (See  <a class="medical medical_basics" href="/d/html/16113.html" rel="external">"Patient education: How to use your metered dose inhaler (adults) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16114.html" rel="external">"Patient education: How to use your dry powder inhaler (adults) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/116647.html" rel="external">"Patient education: How to use your soft mist inhaler (adults) (The Basics)"</a> and  <a class="medical medical_patient" href="/d/html/369.html" rel="external">"Patient education: Inhaler techniques in adults (Beyond the Basics)"</a>.)</p><p class="headingAnchor" id="H74579851"><span class="h2">pMDI technique</span><span class="headingEndMark"> — </span>Important teaching points to emphasize regarding use of pMDI devices include shaking the pMDI before each actuation to ensure consistency of dosing from one actuation to the next and priming the pMDI (wasting four doses, depending on the specific device) before initial use and if it has not been used in two weeks or longer [<a href="#rid97">97-101</a>].</p><p>For administration technique for a specific inhaler, refer to the package insert provided by the manufacturer. The following basic steps for using a pMDI are provided in the table and patient information handout  (<a class="graphic graphic_table graphicRef103302" href="/d/graphic/103302.html" rel="external">table 2</a>). (See  <a class="medical medical_basics" href="/d/html/16113.html" rel="external">"Patient education: How to use your metered dose inhaler (adults) (The Basics)"</a>.)</p><p>pMDI inhalers must be cleaned on a regular basis to prevent medication build up and blockages. Most manufacturers recommend cleaning the mouthpiece at least once per week. To clean the pMDI:</p><p class="bulletIndent1"><span class="glyph">●</span>Remove the medication canister and cap from the mouthpiece. Do not wash the canister or immerse it in water.</p><p class="bulletIndent1"><span class="glyph">●</span>Clean the top and bottom of the plastic mouthpiece by running warm tap water through them for 30 to 60 seconds.</p><p class="bulletIndent1"><span class="glyph">●</span>Shake off excess water and allow the mouthpiece to dry completely (overnight is recommended).</p><p class="bulletIndent1"><span class="glyph">●</span>Replace the canister in the mouthpiece when dry.</p><p class="bulletIndent1"><span class="glyph">●</span>Release one puff from the inhaler into the room away from the patient’s face.</p><p class="bulletIndent1"><span class="glyph">●</span>Replace the mouthpiece cover.</p><p></p><p class="headingAnchor" id="H108641148"><span class="h2">pMDI technique with spacer/chamber</span><span class="headingEndMark"> — </span>Spacers and valved holding chambers are accessory devices that reduce oropharyngeal deposition of pMDI-delivered drug, improve distal delivery, and minimize the importance of hand-breath coordination. New spacer/chamber devices may have a static charge on the inside surface and thus be less effective when it is new compared with after use or washing [<a href="#rid102">102-104</a>]. Washing the device with dishwashing detergent prior to initial use and then allowing it to air dry eliminates this static charge [<a href="#rid105">105,106</a>].</p><p>For a specific spacer/chamber, refer to the package insert provided by the manufacturer. The general technique for using a pMDI with spacer or valved holding chamber is detailed in the table and patient information handout  (<a class="graphic graphic_table graphicRef103303" href="/d/graphic/103303.html" rel="external">table 3</a>) [<a href="#rid66">66,107</a>]. (See  <a class="medical medical_basics" href="/d/html/16113.html" rel="external">"Patient education: How to use your metered dose inhaler (adults) (The Basics)", section on 'How do I use an inhaler with a spacer?'</a>.)</p><p>Discharging multiple doses into the chamber prior to a single inhalation will markedly reduce the amount of respirable drug available compared with individual actuation-inhalation cycles, so this practice should be discouraged [<a href="#rid77">77,108,109</a>].</p><p>Although the powder residue that is deposited on the wall of the chamber is not harmful, the spacer/chamber should be cleaned periodically, approximately every one to two weeks when the spacer/chamber is used daily. Wash the spacer/chamber with warm water and dilute dishwashing detergent. Washing with water alone causes an electrostatic charge to develop, reducing the effectiveness of the spacer [<a href="#rid105">105,106</a>]. After washing, air dry the spacer/chamber before the next use.</p><p class="headingAnchor" id="H3503338"><span class="h2">DPI technique</span><span class="headingEndMark"> — </span>There are many different proprietary dry powder inhaler (DPI) devices, each of which load the initial dose differently. For a specific inhaler, refer to the package insert provided by the manufacturer. The basic steps for using a DPI are provided in the table and the patient information handout  (<a class="graphic graphic_table graphicRef51020" href="/d/graphic/51020.html" rel="external">table 4</a>) [<a href="#rid66">66,107</a>]. (See  <a class="medical medical_basics" href="/d/html/16114.html" rel="external">"Patient education: How to use your dry powder inhaler (adults) (The Basics)"</a>.)</p><p>DPIs come in two main types  (<a class="graphic graphic_picture graphicRef57922" href="/d/graphic/57922.html" rel="external">picture 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple-dose devices, which usually contain enough doses for one month (eg, Handihaler, Diskus, Flexhaler, Ellipta, Pressair, Respi-Click, Digihaler). Among the multiple-dose devices, the method for moving the medication containing powder into the holding chamber is either depressing a lever, opening the cap, or twisting a part of the canister. The RespiClick and Digihaler devices resemble the pMDI in appearance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Single-dose devices  (<a class="graphic graphic_picture graphicRef57922" href="/d/graphic/57922.html" rel="external">picture 2</a>) (eg, <a class="drug drug_general" data-topicid="10300" href="/d/drug information/10300.html" rel="external">tiotropium</a> [Spiriva Handihaler], insulin [Afrezza], levodopa [Inbrija], <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> [Tobi PodHaler], <a class="drug drug_general" data-topicid="9587" href="/d/drug information/9587.html" rel="external">mannitol</a> [Bronchitol], <a class="drug drug_general" data-topicid="10207" href="/d/drug information/10207.html" rel="external">treprostinil</a> [Tyvaso]), require placement of a capsule or a cartridge in the device immediately before each treatment. DPI capsules should NOT be swallowed.</p><p></p><p>Patients will need instructions for and demonstration of the correct use of the specific device they are prescribed. The key points to emphasize are storing the DPI device at room temperature in a dry place, inhaling the medication forcefully and deeply, and not exhaling into the canister [<a href="#rid48">48,49,110-112</a>]. The humid exhaled air can cause the powder to clump, impairing aerosolization and reducing drug delivery to the airways.</p><p>The delivery systems and use of <a class="drug drug_general" data-topicid="99568" href="/d/drug information/99568.html" rel="external">inhaled insulin</a> for diabetes and inhaled <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> powder for cystic fibrosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/1764.html" rel="external">"Inhaled insulin therapy in diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled tobramycin'</a>.)</p><p>DPIs should not be washed with soap and water, as this can cause the medication to clump. The mouthpiece can be cleaned with a dry cloth as needed.</p><p>The In-Check DIAL is a hand-held device to measure inspiratory flow. It is intended to accurately simulate the resistance of a variety of DPIs to enable clinicians to train patients for the proper inspiratory technique, considering force and flow, to achieve optimal deposition in the lungs. Whether or not the use of this device improves patient technique for the use of inhalers is yet to be determined [<a href="#rid113">113-115</a>]. </p><p>Digihalers (eg, ProAir [<a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a>], ArmonAir [<a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a>], AirDuo [<a class="drug drug_general" data-topicid="8730" href="/d/drug information/8730.html" rel="external">fluticasone-salmeterol</a>]) are DPIs with built-in sensors that provide objective data about when the inhaler is used and what inspiratory flow the patient generated. Wireless technology sends the information to the companion mobile app. The mobile app also reminds patients to check their dose counter.</p><p class="headingAnchor" id="H347194516"><span class="h2">Soft mist inhaler technique</span><span class="headingEndMark"> — </span>Soft mist inhalers (SMI) include the Combivent Respimat, Spiriva Respimat, Striverdi Respimat, and Stiolto Respimat [<a href="#rid116">116</a>]. These inhalers all use the same Respimat device  (<a class="graphic graphic_picture graphicRef91634" href="/d/graphic/91634.html" rel="external">picture 3</a>); the basic steps for using an SMI are provided in the table and the patient information handout, as well as the package insert  (<a class="graphic graphic_table graphicRef93600" href="/d/graphic/93600.html" rel="external">table 5</a>). (See  <a class="medical medical_basics" href="/d/html/116647.html" rel="external">"Patient education: How to use your soft mist inhaler (adults) (The Basics)"</a>.)</p><p>Notably, the recommended dose of Combivent is 1 inhalation four times daily, whereas for Spiriva, Striverdi, and Stiolto, 2 puffs once daily are recommended. The SMI does not need to be shaken; priming is done by twisting the clear plastic base before each dose. If the clear plastic base springs back after turning, it was probably not turned until it clicked. When the patient puts their lips on the mouthpiece, the device should be horizontal and pointed towards the pharynx, not the roof of the mouth. The patient's lips should not cover the air vents on the side of the mouthpiece.</p><p>SMIs have an indicator on the side that shows the number of inhalations remaining. When the SMI is empty, the clear base will no longer turn. SMIs should be cleaned once per week by wiping the mouthpiece inside and out with a clean, damp cloth. The SMI can be used with a spacer or VHC [<a href="#rid63">63,117</a>]. </p><p class="headingAnchor" id="H6"><span class="h2">Determining when an inhaler device is empty</span><span class="headingEndMark"> — </span>It is important for the patient to be able to determine when an pMDI canister is empty. All pMDIs are now manufactured with integrated dose counters [<a href="#rid118">118</a>]. This has made obsolete methods that were recommended in the past [<a href="#rid119">119,120</a>]. (See  <a class="medical medical_patient" href="/d/html/369.html" rel="external">"Patient education: Inhaler techniques in adults (Beyond the Basics)"</a>.)</p><p>DPI devices have counters that display the number of puffs remaining or use individual capsules or cartridges that can be counted. SMIs have integrated dose counters. Patients should be instructed to observe the dose counter and to replace the inhaler as indicated.</p><p class="headingAnchor" id="H7"><span class="h1">MECHANICALLY VENTILATED PATIENTS</span><span class="headingEndMark"> — </span>The administration of inhaled medications to mechanically ventilated patients requires special attention because of the propensity for deposition of the medication on ventilator tubing and the endotracheal tube. The methods for delivering inhaled medications to mechanically ventilated patients are discussed separately. (See  <a class="medical medical_review" href="/d/html/552.html" rel="external">"Delivery of inhaled medication in adults", section on 'Mechanically ventilated patients'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16114.html" rel="external">"Patient education: How to use your dry powder inhaler (adults) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16113.html" rel="external">"Patient education: How to use your metered dose inhaler (adults) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/116647.html" rel="external">"Patient education: How to use your soft mist inhaler (adults) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/369.html" rel="external">"Patient education: Inhaler techniques in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H74579735"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaler devices</strong> – Inhaler devices are used to deliver a variety of inhaled medications, most commonly beta-agonists, anticholinergics, and glucocorticoids. Three main types of inhaler devices are available, the pressurized metered dose inhaler (pMDI)  (<a class="graphic graphic_picture graphicRef62613" href="/d/graphic/62613.html" rel="external">picture 1</a>), the dry powder inhaler (DPI)  (<a class="graphic graphic_picture graphicRef57922" href="/d/graphic/57922.html" rel="external">picture 2</a>), and the soft mist inhaler (SMI)  (<a class="graphic graphic_picture graphicRef91634" href="/d/graphic/91634.html" rel="external">picture 3</a>). (See <a class="local">'Types of inhaler devices'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common problems with inhaler devices</strong> – Common problems with inhaler usage are deposition of medication in the oropharynx, poor coordination of actuation and inhalation, and insufficient breath-hold after inhalation. Correct technique for using inhaler devices delivers the medication to the airways of the lung with minimal oropharyngeal deposition, leading to better airway responses. Furthermore, poor adherence with inhaler use compromises the effectiveness of inhaled therapies in patients with asthma and COPD.</p><p></p><p class="bulletIndent1">(See <a class="local">'Common problems with inhaler devices'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies to improve inhaled drug delivery</strong> – For patients who have difficulty with proper pMDI technique and for those who are using glucocorticoid-containing pMDIs, use of a spacer device or valved holding chamber reduces oropharyngeal deposition and improves coordination of actuation and inhalation. DPI and SMI inhalers are additional methods to address actuation-inhalation problems. (See <a class="local">'Actuation-inhalation coordination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>pMDI technique</strong> – The basic steps for using a pMDI are provided in the tables  (<a class="graphic graphic_table graphicRef103302" href="/d/graphic/103302.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef103303" href="/d/graphic/103303.html" rel="external">table 3</a>) and in the Patient education handout. (See  <a class="medical medical_basics" href="/d/html/16113.html" rel="external">"Patient education: How to use your metered dose inhaler (adults) (The Basics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DPI and SMI technique</strong> – The basic steps for using a DPI or an SMI are provided in the tables  (<a class="graphic graphic_table graphicRef51020" href="/d/graphic/51020.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef93600" href="/d/graphic/93600.html" rel="external">table 5</a>) and also in the Patient education handouts. (See  <a class="medical medical_basics" href="/d/html/16114.html" rel="external">"Patient education: How to use your dry powder inhaler (adults) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/116647.html" rel="external">"Patient education: How to use your soft mist inhaler (adults) (The Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H3542384058"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William Bailey, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Al-Jahdali H, Ahmed A, Al-Harbi A, et al. Improper inhaler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin Immunol 2013; 9:8.</a></li><li><a class="nounderline abstract_t">Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. J Allergy Clin Immunol Pract 2017; 5:1071.</a></li><li><a class="nounderline abstract_t">Goodman DE, Israel E, Rosenberg M, et al. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med 1994; 150:1256.</a></li><li><a class="nounderline abstract_t">Toogood, JH. Helping your patients make better use of MDIs and spacers. J Respir Dis 1994; 15:151.</a></li><li><a class="nounderline abstract_t">Sander N, Fusco-Walkert SJ, Harder JM, Chipps BE. Dose counting and the use of pressurized metered-dose inhalers: running on empty. Ann Allergy Asthma Immunol 2006; 97:34.</a></li><li><a class="nounderline abstract_t">Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008; 75:18.</a></li><li><a class="nounderline abstract_t">Souza ML, Meneghini AC, Ferraz E, et al. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J Bras Pneumol 2009; 35:824.</a></li><li><a class="nounderline abstract_t">Sleath B, Ayala GX, Gillette C, et al. Provider demonstration and assessment of child device technique during pediatric asthma visits. Pediatrics 2011; 127:642.</a></li><li><a class="nounderline abstract_t">Minai BA, Martin JE, Cohn RC. Results of a physician and respiratory therapist collaborative effort to improve long-term metered-dose inhaler technique in a pediatric asthma clinic. Respir Care 2004; 49:600.</a></li><li><a class="nounderline abstract_t">Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. Int J Clin Pract 2009; 63:1150.</a></li><li><a class="nounderline abstract_t">Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16:249.</a></li><li><a class="nounderline abstract_t">Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105:930.</a></li><li><a class="nounderline abstract_t">Sanchis J, Gich I, Pedersen S, Aerosol Drug Management Improvement Team (ADMIT). Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time? Chest 2016; 150:394.</a></li><li><a class="nounderline abstract_t">Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008; 3:371.</a></li><li><a class="nounderline abstract_t">Sulaiman I, Cushen B, Greene G, et al. Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2017; 195:1333.</a></li><li><a class="nounderline abstract_t">Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013; 107:1481.</a></li><li><a class="nounderline abstract_t">Small M, Anderson P, Vickers A, et al. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther 2011; 28:202.</a></li><li><a class="nounderline abstract_t">Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011; 377:1032.</a></li><li><a class="nounderline abstract_t">Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37:1308.</a></li><li><a class="nounderline abstract_t">Stein SW, Thiel CG. The History of Therapeutic Aerosols: A Chronological Review. J Aerosol Med Pulm Drug Deliv 2017; 30:20.</a></li><li><a class="nounderline abstract_t">Hawksworth RJ, Sykes AP, Faris M, et al. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2002; 88:473.</a></li><li><a class="nounderline abstract_t">Langley SJ, Sykes AP, Batty EP, et al. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Ann Allergy Asthma Immunol 2002; 88:488.</a></li><li><a class="nounderline abstract_t">Cheng YS, Fu CS, Yazzie D, Zhou Y. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med 2001; 14:255.</a></li><li><a class="nounderline abstract_t">Richards J, Hirst P, Pitcairn G, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001; 14:197.</a></li><li><a class="nounderline abstract_t">Boccuzzi SJ, Wogen J, Roehm JB. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. Clin Ther 2000; 22:237.</a></li><li><a class="nounderline abstract_t">Huchon G, Hofbauer P, Cannizzaro G, et al. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur Respir J 2000; 15:663.</a></li><li><a class="nounderline abstract_t">Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir Med 2000; 94:549.</a></li><li><a class="nounderline abstract_t">Shapiro G, Bronsky E, Murray A, et al. Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma. Arch Pediatr Adolesc Med 2000; 154:1219.</a></li><li><a class="nounderline abstract_t">Brindley A. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability. J Allergy Clin Immunol 1999; 104:S221.</a></li><li><a class="nounderline abstract_t">Bronsky E, Ekholm BP, Klinger NM, Colice GL. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. J Asthma 1999; 36:107.</a></li><li><a class="nounderline abstract_t">Ramsdell JW, Klinger NM, Ekholm BP, Colice GL. Safety of long-term treatment with HFA albuterol. Chest 1999; 115:945.</a></li><li><a class="nounderline abstract_t">Bleecker ER, Tinkelman DG, Ramsdell J, et al. Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. Chest 1998; 113:283.</a></li><li><a class="nounderline abstract_t">Leach CL. The CFC to HFA transition and its impact on pulmonary drug development. Respir Care 2005; 50:1201.</a></li><li><a class="nounderline abstract_t">Roche N, Dekhuijzen PN. The Evolution of Pressurized Metered-Dose Inhalers from Early to Modern Devices. J Aerosol Med Pulm Drug Deliv 2016; 29:311.</a></li><li><a class="nounderline abstract_t">Smyth HD. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev 2003; 55:807.</a></li><li><a class="nounderline abstract_t">Escribano A, Tutuncu A, Löhr I, et al. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial. Curr Med Res Opin 2006; 22:1085.</a></li><li><a class="nounderline abstract_t">Singh D, Tutuncu A, Lohr I, et al. Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence. Int J Clin Pharmacol Ther 2007; 45:485.</a></li><li><a class="nounderline abstract_t">Shapiro GS, Klinger NM, Ekholm BP, Colice GL. Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma. J Asthma 2000; 37:667.</a></li><li><a class="nounderline abstract_t">Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100:375.</a></li><li><a class="nounderline abstract_t">Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005; 61:203.</a></li><li><a class="nounderline abstract_t">Leach CL, Colice GL. A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times. J Aerosol Med Pulm Drug Deliv 2010; 23:355.</a></li><li><a class="nounderline abstract_t">Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir 2012; 28:15015.</a></li><li><a class="nounderline abstract_t">Doty A, Schroeder J, Vang K, et al. Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability. AAPS PharmSciTech 2018; 19:837.</a></li><li><a class="nounderline abstract_t">Ferguson GT, Hickey AJ, Dwivedi S. Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respir Med 2018; 134:16.</a></li><li><a class="nounderline abstract_t">Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96:293.</a></li><li><a class="nounderline abstract_t">Islam N, Gladki E. Dry powder inhalers (DPIs)--a review of device reliability and innovation. Int J Pharm 2008; 360:1.</a></li><li><a class="nounderline abstract_t">Yang MY, Chan JG, Chan HK. Pulmonary drug delivery by powder aerosols. J Control Release 2014; 193:228.</a></li><li><a class="nounderline abstract_t">Broeders ME, Molema J, Vermue NA, Folgering HT. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J 2001; 18:780.</a></li><li><a class="nounderline abstract_t">Chavan V, Dalby R. Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers. AAPS PharmSci 2000; 2:E10.</a></li><li><a class="nounderline abstract_t">Kanabuchi K, Kondo T, Tanigaki T, et al. Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship. Tokai J Exp Clin Med 2011; 36:1.</a></li><li><a class="nounderline abstract_t">Clark AR. Analyzing 20 years of clinical studies on inspiration through dry powder inhalers. Proc Respir Drug Deliv 2016; 1:99.</a></li><li><a class="nounderline abstract_t">Clark AR, Weers JG, Dhand R. The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates. J Aerosol Med Pulm Drug Deliv 2020; 33:1.</a></li><li><a class="nounderline abstract_t">Weers J, Clark A. The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers. Pharm Res 2017; 34:507.</a></li><li><a class="nounderline abstract_t">Pleasants RA. Dry Powder Inhalers and Humidity: Another Factor to Consider to Ensure Adequate Lung Delivery. Ann Am Thorac Soc 2017; 14:1602.</a></li><li><a class="nounderline abstract_t">Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 2004; 283:1.</a></li><li><a class="nounderline abstract_t">Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med 1999; 12 Suppl 1:S19.</a></li><li><a class="nounderline abstract_t">Hochrainer D, Hölz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005; 18:273.</a></li><li><a class="nounderline abstract_t">Dhand R. Aerosol plumes: slow and steady wins the race. J Aerosol Med 2005; 18:261.</a></li><li><a class="nounderline abstract_t">Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113:957.</a></li><li><a class="nounderline abstract_t">Panos RJ. Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013; 8:221.</a></li><li><a class="nounderline abstract_t">Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006; 1:251.</a></li><li><a class="nounderline abstract_t">van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009; 103:22.</a></li><li class="breakAll">Spiriva Respimat [package insert]. CT: Boehringer Ingelheim; 2017.</li><li><a class="nounderline abstract_t">Wilkes W, Fink J, Dhand R. Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J Aerosol Med 2001; 14:351.</a></li><li><a class="nounderline abstract_t">Nikander K, Nicholls C, Denyer J, Pritchard J. The evolution of spacers and valved holding chambers. J Aerosol Med Pulm Drug Deliv 2014; 27 Suppl 1:S4.</a></li><li><a class="nounderline abstract_t">Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000; 45:874.</a></li><li><a class="nounderline abstract_t">Vincken W, Levy ML, Scullion J, et al. Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res 2018; 4.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on June 13, 2011).</li><li><a class="nounderline abstract_t">Dempsey OJ, Wilson AM, Coutie WJ, Lipworth BJ. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Chest 1999; 116:935.</a></li><li><a class="nounderline abstract_t">Dissanayake S, Suggett J. A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu Anti-static VHC. Ther Adv Respir Dis 2018; 12:1753465817751346.</a></li><li><a class="nounderline abstract_t">Sheth P, Bertsch MD, Knapp CL, Myrdal PB. In vitro evaluation of nonconventional accessory devices for pressurized metered-dose inhalers. Ann Allergy Asthma Immunol 2014; 113:55.</a></li><li><a class="nounderline abstract_t">Clark DJ, Lipworth BJ. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax 1996; 51:981.</a></li><li><a class="nounderline abstract_t">Slator L, von Hollen D, Sandell D, Hatley RH. In vitro comparison of the effect of inhalation delay and flow rate on the emitted dose from three valved holding chambers. J Aerosol Med Pulm Drug Deliv 2014; 27 Suppl 1:S37.</a></li><li><a class="nounderline abstract_t">Berg E, Madsen J, Bisgaard H. In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur Respir J 1998; 12:472.</a></li><li><a class="nounderline abstract_t">Rau JL, Coppolo DP, Nagel MW, et al. The importance of nonelectrostatic materials in holding chambers for delivery of hydrofluoroalkane albuterol. Respir Care 2006; 51:503.</a></li><li><a class="nounderline abstract_t">Burudpakdee C, Kushnarev V, Coppolo D, Suggett JA. A Retrospective Study of the Effectiveness of the AeroChamber Plus® Flow-Vu® Antistatic Valved Holding Chamber for Asthma Control. Pulm Ther 2017; 3:283.</a></li><li><a class="nounderline abstract_t">O'Callaghan C, Barry P. Spacer devices in the treatment of asthma. BMJ 1997; 314:1061.</a></li><li><a class="nounderline abstract_t">Barry PW, O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax 1996; 51:835.</a></li><li><a class="nounderline abstract_t">Bisgaard H, Anhøj J, Klug B, Berg E. A non-electrostatic spacer for aerosol delivery. Arch Dis Child 1995; 73:226.</a></li><li><a class="nounderline abstract_t">Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care 2008; 53:699.</a></li><li class="breakAll">Guidelines for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Program, NIH publication no. 97-4051 USDHHS, 1997.</li><li><a class="nounderline abstract_t">Pickering H, Pitcairn GR, Hirst PH, et al. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. Clin Ther 2000; 22:1483.</a></li><li><a class="nounderline abstract_t">Dickens GR, Wermeling DP, Matheny CJ, et al. Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration. Ann Allergy Asthma Immunol 2000; 84:528.</a></li><li><a class="nounderline abstract_t">Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999; 104:S250.</a></li><li><a class="nounderline abstract_t">Dekhuijzen R, Lavorini F, Usmani OS, van Boven JFM. Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here? J Allergy Clin Immunol Pract 2018; 6:785.</a></li><li><a class="nounderline abstract_t">Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63:831.</a></li><li><a class="nounderline abstract_t">Vrijens B, Dima AL, Van Ganse E, et al. What We Mean When We Talk About Adherence in Respiratory Medicine. J Allergy Clin Immunol Pract 2016; 4:802.</a></li><li><a class="nounderline abstract_t">Tommelein E, Mehuys E, Van Tongelen I, et al. Accuracy of the Medication Adherence Report Scale (MARS-5) as a quantitative measure of adherence to inhalation medication in patients with COPD. Ann Pharmacother 2014; 48:589.</a></li><li><a class="nounderline abstract_t">Rand CS, Nides M, Cowles MK, et al. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med 1995; 152:580.</a></li><li><a class="nounderline abstract_t">Chan AHY, Pleasants RA, Dhand R, et al. Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective. Pulm Ther 2021; 7:345.</a></li><li><a class="nounderline abstract_t">Pleasants RA, Chan AH, Mosnaim G, et al. Integrating digital inhalers into clinical care of patients with asthma and chronic obstructive pulmonary disease. Respir Med 2022; 205:107038.</a></li><li><a class="nounderline abstract_t">van Boven JF, Chavannes NH, van der Molen T, et al. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med 2014; 108:103.</a></li><li><a class="nounderline abstract_t">Zafari Z, Lynd LD, FitzGerald JM, Sadatsafavi M. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study. J Allergy Clin Immunol 2014; 134:908.</a></li><li class="breakAll">National Asthma Education Program. Teach your patients about asthma. A clinician's guide. National Institutes of Health, Bethesda, 1992, Pub. #92-2737.</li><li><a class="nounderline abstract_t">Takaku Y, Kurashima K, Ohta C, et al. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? Respir Med 2017; 123:110.</a></li><li><a class="nounderline abstract_t">Manzella BA, Brooks CM, Richards JM Jr, et al. Assessing the use of metered dose inhalers by adults with asthma. J Asthma 1989; 26:223.</a></li><li><a class="nounderline abstract_t">Blake KV, Harman E, Hendeles L. Evaluation of a generic albuterol metered-dose inhaler: importance of priming the MDI. Ann Allergy 1992; 68:169.</a></li><li><a class="nounderline abstract_t">Ross RN. Loss of bronchodilator medication in priming a conventional metered dose inhaler: a cost of treating asthma. Med Interface 1997; 10:141.</a></li><li><a class="nounderline abstract_t">Cyr TD, Graham SJ, Li KY, Lovering EG. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 1991; 8:658.</a></li><li><a class="nounderline abstract_t">Everard ML, Devadason SG, Summers QA, Le Souëf PN. Factors affecting total and "respirable" dose delivered by a salbutamol metered dose inhaler. Thorax 1995; 50:746.</a></li><li><a class="nounderline abstract_t">Berg E. In vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med 1995; 8 Suppl 3:S3.</a></li><li><a class="nounderline abstract_t">Dompeling E, Oudesluys-Murphy AM, Janssens HM, et al. Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge. Arch Dis Child 2001; 84:178.</a></li><li><a class="nounderline abstract_t">Anhøj J, Bisgaard H, Lipworth BJ. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. Br J Clin Pharmacol 1999; 47:333.</a></li><li><a class="nounderline abstract_t">van der Veen MJ, van der Zee JS. Aerosol recovery from large-volume reservoir delivery systems is highly dependent on the static properties of the reservoir. Eur Respir J 1999; 13:668.</a></li><li><a class="nounderline abstract_t">Wildhaber JH, Janssens HM, Piérart F, et al. High-percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000; 29:389.</a></li><li><a class="nounderline abstract_t">Piérart F, Wildhaber JH, Vrancken I, et al. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J 1999; 13:673.</a></li><li><a class="nounderline abstract_t">Kacmarek, DM, Hess, D. The interface between patient and aerosol generator. Respir Care 1991; 36:952.</a></li><li><a class="nounderline abstract_t">Rau JL, Restrepo RD, Deshpande V. Inhalation of single vs multiple metered-dose bronchodilator actuations from reservoir devices. An in vitro study. Chest 1996; 109:969.</a></li><li><a class="nounderline abstract_t">Barry PW, O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 1995; 40:76.</a></li><li><a class="nounderline abstract_t">Smith KJ, Chan HK, Brown KF. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J Aerosol Med 1998; 11:231.</a></li><li><a class="nounderline abstract_t">Azouz W, Chetcuti P, Hosker HS, et al. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv 2015; 28:35.</a></li><li><a class="nounderline abstract_t">Kocks J, Bosnic-Anticevich S, van Cooten J, et al. Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study. BMC Pulm Med 2023; 23:302.</a></li><li><a class="nounderline abstract_t">Kawamatawong T, Khiawwan S, Pornsuriyasak P. Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases. J Asthma Allergy 2017; 10:17.</a></li><li><a class="nounderline abstract_t">Manuyakorn W, Direkwattanachai C, Benjaponpitak S, et al. Sensitivity of Turbutester and Accuhaler tester in asthmatic children and adolescents. Pediatr Int 2010; 52:118.</a></li><li><a class="nounderline abstract_t">Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med 2003; 97:181.</a></li><li class="breakAll">Combivent Respimat prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s013lbl.pdf (Accessed on December 19, 2016).</li><li><a class="nounderline abstract_t">Ogasawara T, Sakata J, Aoshima Y, et al. Bronchodilator Effect of Tiotropium via Respimat®Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD). Intern Med 2017; 56:2401.</a></li><li><a class="nounderline abstract_t">Rickard KA. Not running on empty. Ann Allergy Asthma Immunol 2006; 97:558.</a></li><li><a class="nounderline abstract_t">Cain WT, Oppenheimer JJ. The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices. Ann Allergy Asthma Immunol 2001; 87:417.</a></li><li><a class="nounderline abstract_t">Ogren RA, Baldwin JL, Simon RA. How patients determine when to replace their metered-dose inhalers. Ann Allergy Asthma Immunol 1995; 75:485.</a></li></ol></div><div id="topicVersionRevision">Topic 559 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23510684" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Improper inhaler technique is associated with poor asthma control and frequent emergency department visits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286157" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7952549" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The influence of age, diagnosis, and gender on proper use of metered-dose inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Helping your patients make better use of MDIs and spacers</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16892778" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dose counting and the use of pressurized metered-dose inhalers: running on empty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17911976" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dry powder inhalers: which factors determine the frequency of handling errors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820807" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Knowledge of and technique for using inhalation devices among asthma patients and COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444594" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Provider demonstration and assessment of child device technique during pediatric asthma visits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15165293" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Results of a physician and respiratory therapist collaborative effort to improve long-term metered-dose inhaler technique in a pediatric asthma clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624784" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14572322" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367593" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Inhaler mishandling remains common in real life and is associated with reduced disease control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060726" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990964" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Medication adherence issues in patients treated for COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27409253" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23643487" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21331556" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21036392" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Aerosol drug delivery: developments in device design and clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310878" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : What the pulmonary specialist should know about the new inhalation therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27748638" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The History of Therapeutic Aerosols: A Chronological Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12027068" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12027070" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11681657" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11681651" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10743983" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10780756" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10921758" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115306" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588978" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10077140" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10208190" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety of long-term treatment with HFA albuterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498940" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16122403" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The CFC to HFA transition and its impact on pulmonary drug development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26824873" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Evolution of Pressurized Metered-Dose Inhalers from Early to Modern Devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12842602" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16846541" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17907591" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11192231" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275052" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824911" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20575669" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22985189" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29019170" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29413503" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12113378" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evolution of dry powder inhaler design, formulation, and performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18583072" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dry powder inhalers (DPIs)--a review of device reliability and innovation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24818765" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pulmonary drug delivery by powder aerosols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11757627" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11741226" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21547884" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Minimal inspiratory flow from dry powder inhalers according to a biphasic model of pressure vs. flow relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Analyzing 20 years of clinical studies on inspiration through dry powder inhalers</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613682" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27738953" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28696775" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dry Powder Inhalers and Humidity: Another Factor to Consider to Ensure Adequate Lung Delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15363496" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A review of the development of Respimat Soft Mist Inhaler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10623337" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Optimizing the in vitro performance of Respimat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16181002" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16181000" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Aerosol plumes: slow and steady wins the race.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554631" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23658481" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046862" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Use of Respimat Soft Mist inhaler in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19022642" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19022642" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11693847" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25054481" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The evolution of spacers and valved holding chambers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926386" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Aerosol device selection: evidence to practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29928649" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Spacer devices for inhaled therapy: why use them, and how?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29928649" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Spacer devices for inhaled therapy: why use them, and how?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10531156" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29378477" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu Anti-static VHC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24814758" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : In vitro evaluation of nonconventional accessory devices for pressurized metered-dose inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8977596" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476047" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : In vitro comparison of the effect of inhalation delay and flow rate on the emitted dose from three valved holding chambers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9727804" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638160" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The importance of nonelectrostatic materials in holding chambers for delivery of hydrofluoroalkane albuterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32026345" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A Retrospective Study of the Effectiveness of the AeroChamber Plus®Flow-Vu®Antistatic Valved Holding Chamber for Asthma Control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9133878" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Spacer devices in the treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8795674" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Inhalational drug delivery from seven different spacer devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492160" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A non-electrostatic spacer for aerosol delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18501026" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Aerosol delivery devices in the treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18501026" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Aerosol delivery devices in the treatment of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11192139" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831007" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588985" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29339126" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18728206" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Patient adherence in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27587314" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : What We Mean When We Talk About Adherence in Respiratory Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24523393" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Accuracy of the Medication Adherence Report Scale (MARS-5) as a quantitative measure of adherence to inhalation medication in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7633711" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34379316" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36446239" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Integrating digital inhalers into clinical care of patients with asthma and chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24070566" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Clinical and economic impact of non-adherence in COPD: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24875619" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24875619" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28137486" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2702229" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Assessing the use of metered dose inhalers by adults with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739192" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Evaluation of a generic albuterol metered-dose inhaler: importance of priming the MDI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10166801" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Loss of bronchodilator medication in priming a conventional metered dose inhaler: a cost of treating asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1866384" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Low first-spray drug content in albuterol metered-dose inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7570408" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Factors affecting total and "respirable" dose delivered by a salbutamol metered dose inhaler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10157897" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : In vitro properties of pressurized metered dose inhalers with and without spacer devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11159302" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215759" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232444" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Aerosol recovery from large-volume reservoir delivery systems is highly dependent on the static properties of the reservoir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10790251" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : High-percentage lung delivery in children from detergent-treated spacers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232445" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The interface between patient and aerosol generator</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635379" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Inhalation of single vs multiple metered-dose bronchodilator actuations from reservoir devices. An in vitro study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8527272" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10346666" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24815999" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The inhalation characteristics of patients when they use different dry powder inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37592263" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28260934" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508454" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Sensitivity of Turbutester and Accuhaler tester in asthmatic children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12587970" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12587970" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28824055" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Bronchodilator Effect of Tiotropium via Respimat®Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17069115" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Not running on empty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11730185" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8603277" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : How patients determine when to replace their metered-dose inhalers.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
